Disease · MONDO_0020283
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Methotrexate vs Mycophenolate Mofetil: deaths from any cause | 1 of 107 | 0 of 109 | 216 | NCT01829295 | Trial comparisons |
| Methotrexate vs Mycophenolate Mofetil: serious adverse events | 7 of 107 | 7 of 109 | 216 | NCT01829295 | Trial comparisons |
| Methotrexate vs Mycophenolate Mofetil: Number of Participants Achieving Treatment Success at 6 Months (Phase I, 0-6 Months) | 64 of 96 | 56 of 98 | 194 | NCT01829295 | Trial comparisons |
| FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months | 47 of 101 | 39 of 52 | 153 | NCT02746991 | Trial comparisons |
| FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months | 22 of 101 | 28 of 52 | 153 | NCT02746991 | Trial comparisons |
| FAI Insert vs Sham Injection: deaths from any cause | 0 of 101 | 0 of 52 | 153 | NCT02746991 | Trial comparisons |
| FAI Insert vs Sham Injection: serious adverse events | 21 of 101 | 7 of 52 | 153 | NCT02746991 | Trial comparisons |
| Methotrexate vs Mycophenolate Mofetil: Number of Participants Achieving Treatment Success at 12 Months on Same Medication (Phase I, 6-12 Months) | 48 of 60 | 40 of 54 | 114 | NCT01829295 | Trial comparisons |
| Methotrexate vs Mycophenolate Mofetil: serious adverse events | 0 of 41 | 1 of 39 | 80 | NCT01232920 | Trial comparisons |
| Filgotinib vs Placebo: deaths from any cause | 0 of 38 | 0 of 36 | 74 | NCT03207815 | Trial comparisons |
| Filgotinib vs Placebo: serious adverse events | 5 of 37 | 2 of 35 | 72 | NCT03207815 | Trial comparisons |
| Methotrexate vs Mycophenolate Mofetil: Number of Participants Achieving Treatment Success | 24 of 35 | 15 of 32 | 67 | NCT01232920 | Trial comparisons |
| Switched Over to Methotrexate vs Switched Over to Mycophenolate Mofetil: Number of Participants Achieving Treatment Success After Switching to Other Medication (Phase II, 0-6 Months) | 20 of 29 | 7 of 20 | 49 | NCT01829295 | Trial comparisons |
| Intravitreal Injection vs Subconjunctival Injection: Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) | 4 of 15 | 4 of 15 | 30 | NCT00908466 | Trial comparisons |
| Intravitreal Injection vs Subconjunctival Injection: serious adverse events | 1 of 15 | 0 of 15 | 30 | NCT00908466 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020283/comparisons